(NYSE: BWXT) announced today that its BWXT Advanced Fuels subsidiary has entered into a multi-year commercial agreement with ...
The issuance of Common Shares was approved by the TSX Venture Exchange (the "TSXV") on October 5, 2026.
A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results